Caplin Point has been a star performer, but can it maintain its momentum? As it ventures into competitive LATAM markets, scales its US sterile portfolio, and explores complex molecules, challenges are mounting. Is now the time to rethink your position? Sai Prabhakar from The Hindu Business Line shares key insights and why we’re revising our rating.